secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexentis Technologies Inc. (NXTS)
CIK:        0001789192
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001493152-25-019064
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

N2OFF closes acquisition of MitoCareX, issuing stock and $700K cash for 100% of biotech
--------------------------------------------------------------------------------

- Acquired 100% of MitoCareX, a drug discovery company targeting resistant cancers including pancreatic and non-small cell lung cancer.
- Consideration: $700,000 cash to SciSparc and ~1.17M shares (40% of N2OFF fully diluted capital) to the Sellers.
- Sellers entitled to 30% of N2OFF financing proceeds (capped at $1.6M) for 5 years and milestone issuances up to 25% additional stock.
- Board overlap: N2OFF Chairman Amitay Weiss and Director Liat Sidi also serve on SciSparc's board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225019064/0001493152-25-019064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789192/000149315225019064/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer